Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income margin | (754.2%) | (760.5%) | (146.7%) | (183.1%) | (28.9%) | (47.9%) | (44.1%) | (66.2%) | (194.0%) | (197.0%) | (801.0%) | (720.3%) | (900.3%) | (556.2%) | (1,087.6%) | (427.5%) | (168.1%) | (83.9%) | (75.7%) | (15.4%) |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Operating Income margin is (9.0%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Operating Income margin for Alnylam Pharmaceuticals, Inc. have been (61.9%) over the past three years, and (143.5%) over the past five years.
As of today, Alnylam Pharmaceuticals, Inc.'s Operating Income margin is (9.0%), which is higher than industry median of (915.3%). It indicates that Alnylam Pharmaceuticals, Inc.'s Operating Income margin is Good.